Terminalia chebula (fruit) prevents liver toxicity caused by sub-chronic administration of rifampicin, isoniazid and pyrazinamide in combination

Human and Experimental Toxicology

Volumn 25, Issue 3, 2006, Pages 111-118

  Tasduq, S A ^a   Singh, K ^a   Satti, N K ^a   Gupta, D K ^a   Suri, K A ^a   Johri, R K ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Anti oxidant; Chebuloside II; Hepatotoxicity; Isoniazid; Pyrazinamide; Rifampicin; Terminalia chebula

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TERMINALIA CHEBULA EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TERMINALIA CHEBULA;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; CELL SURVIVAL; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; FRUIT; HEPATITIS, TOXIC; HEPATOCYTES; ISONIAZID; LIPID PEROXIDATION; OXIDATIVE STRESS; PYRAZINAMIDE; RATS; RIFAMPIN; TERMINALIA;

ANIMALIA; TERMINALIA CHEBULA;

EID: 33645984612     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327106ht601oa     Document Type: Article

References (29)

1. Mhaskar KS, Blatter E, Caius JF eds. Kiritikar & Basu's illustrated Indian medicinal plants, Volume 5. Satguru Publications 2000: 1424-27.
2. Chatterjee S, Pakrasi SC. The treatise on Indian medicinal plants, Volume 3. National Institute of Science Communication and Information Resources 2000: 203-204.
3. Tasaduq SA, Singh K, Sethi S, Sharma SC, Bedi KL, Singh J et al. Hepatoprotective and antioxidant profile of HP-1, a polyherbal phytomedicine. Hum Exp Toxicol 2003; 22: 639-46.
4. Malekzadeh F, Ehsanifar H, Shahamat M, Levin M, Colwell RR. Antibacterial activity of black myrobalan (Terminalia chebula Retz) against Helicobacter pylori. Int J Antimicrob Agents 2002; 18: 85-88.
5. Shin TY, Jeong HJ, Kim DK, Kim SH, Lee JK, Kum DK et al. Inhibitory action of water soluble fraction of Terminalia chebula on systemic and local anaphylaxis. J Ethnopharmacol 2001; 74: 133-40.
6. Vonshak A, Barazani O, Sathiyamoorthy P, Shalev R, Vardy D, Golan-Goldhirsh A. Screening South Indian medicinal plants for antifungal activity against cutaneous pathogens. Phytother Res 2003; 17: 1123-25.
7. Cheng HY, Lin TC, Yu KH, Yang CM, Lin CC. Antioxidant and free radical scavenging activities of Terminalia chebula. Biol Pharm Bull 2003; 26: 1331-35.
8. Suguna L, Singh S, Sivakumar P, Sampath P, Chandrakasan G. Influence of Terminalia chebula on dermal wound healing in rats. Phytother Res 2002; 16: 227-31.
9. Saleem A, Husheem M, Harkonen P, Pihlaja K. Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula Retz fruit. J Ethnopharmacol 2002; 81: 327-36.
10. Sabu MC, Kuttan R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol 2002; 81: 155-60.
11. Ahn MJ, Kim CY, Lee JS, Kim TG, Kim SH, Lee CK et al. Inhibition of HIV-1 integrase by galloyl glucoses from Terminalia chebula and flavonol glycoside gallates from Euphorbia pekinensis. Planta Med 2000; 68: 457-59.
12. Kour S, Grover IS, Singh M, Kaur S. Antimutagenicity of hydrolyzable tannins from Terminalia chebula in Salmonella typhimurium. Mutat Res 1998; 419: 169-79.
13. Tamhane MD, Thorat SP, Rege NN, Dahanukar SA. Effect of oral administration of Terminalia chebula on gastric emptying: an experimental study. J Postgrad Med 1997; 43: 12-13.
14. Sohni YR, Bhatt RM. Activity of a crude extract formulation in experimental hepatic amoebiasis and in immunomodulation studies. J Ethnopharmacol 1996; 54: 119-24.
15. Kundu AP, Mahato SB. Triterpenoids and their glycosides from Terminalia chebula. Phytochemistry 1993; 32: 999-1002.
16. Reen RK, Karan M, Singh K, Karan V, Johri RK, Singh J. Screening of various Swertia species extracts in primary monolayer cultures of rat hepatocytes against carbon tetrachloride- and paracetamol-induced toxicity. J Ethnopharmacol 2001; 75: 239-47.
17. Germano MP, Angelo VD, Sanogo R, Catania S, Alma R, De Pasquale R et al. Hepatoprotective and antibacterial effects of extracts from Trichilia emetica Vahl. (Meliaceae). J Ethnopharmacol 2005; 96: 227-32.
18. Tasduq SA, Kaiser P, Koul S, Bhat R, Johri RK. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol Res 2005; 31: 132-35.
19. Post R, Sen AK. Sodium and potassium stimulated ATPase. In Estabrook RW, Pullman ME eds. Methods Enzymology. Academic Press, 1967: 762-68.
20. Minotti G, Aust SD. The requirement of iron (III) in the initiation of lipid peroxidation by iron (II) and hydrogen peroxide. J Biol Chem 1987; 262: 1098-104.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
22. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC et al. Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
23. Wang C-J, Wang J-M, Lin W-L, Chu C-Y et al. Protective effect of hibiscus anthocyanins against ter-butyl hydroperoxide induced hepatic toxicity in rats. Food Chem Toxicol 2000; 38: 411-16.
24. Caro AA, Cederbaum AI. Oxidative stress, toxicology and pharmacology of CYP 2E1. Ann Rev Pharmacol Toxicol 2004; 44: 27-42.
25. Freel RW, Goldner AM. Sodium coupled-electrolyte transport across epithelial layer: emerging concepts and directions. Am J Physiol 1981; 241: G451-60.
26. Garza-Ocana A, Zanatta-Calderon N, Acosta D, Torres-Alanis O, Pineyro-Lopez A. Production of reactive oxygen species by toxin T-514 of genus Karwinskia in vitro. Toxicol In Vitro 2003; 17: 19-25.
27. Micu AL, Miksys S, Sellers E, Koop DR, Tyndale RF. Rat hepatic CYP 2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. J Pharm Exp Ther 2003; 306: 941-47.
28. Morimoto M, Zern MA, Hagbjork AL, Ingelman-Sundberg M, French SW. Fish oil, alcohol and liver pathology. Role of cytochrome P450 2E1. Proc Soc Exp Biol Med 1994; 207: 197-205.
29. 4-induced liver cirrhosis by silymarin. Fund Clin Pharm 1989; 3: 183-91.